Press Releases.

- Phase II Study Evaluating the Combination of RG-101 and GSK's Long-Acting Parenteral (LAP) Formulation of GSK2878175 as a potential single-visit cure to begin Q4 2016

- Continued High Virologic Response Rates across All Treatment Arms Out through 24 weeks of Follow Up -

-Oral presentation during general session on interim RG-101 Phase II results & three posters to be presented-

- RG-101 Containing Regimen Has Potential to Reduce Harvoni®, Olysio®, or Daklinza™ Rx to 4 Week Duration -

- Additional studies on track for enrollment in H12016 with multiple data read-outs expected throughout 2016 -

-Regulus Earns $10.0 Million Milestone Payment from AstraZeneca and Achieves Key Goal for 2015-

-Expanded Development of RG-101 through Clinical Trial Collaboration with GSK to Achieve Potential Single Visit HCV Therapy -

- Long-Acting Parenteral Formulation of GSK2878175 Being Developed; Co-Administration with RG-101 May Enable Single Visit Therapy for HCV Patients

RG-012 Shown to Directly Inhibit microRNA-21, Demonstrates Favorable Preclinical Profile Supporting Proof of Mechanism and Clinical Development

-Phase I Clinical Data will be Featured in Viral Hepatitis Plenary Session-

-Advanced 'Clinical Map Initiative' with Start of Key Clinical Trials for RG-101 and RG-012-

-Achieves Key 'Clinical Map Initiative' Goal for 2015 and Advances Orphan Disease Efforts-

- Paul Grint, M.D. Appointed as President and Chief Executive Officer and as a Member of the Board of Directors-

- Advanced 'Clinical Map Initiative' with Positive Results on RG-101 and Selection of RG-125 as 3rd Clinical Candidate -

-RG-101 Achieves Sustained HCV Viral Suppression with Favorable Safety and Tolerability-

-Late-breaking data featured in oral presentation; three additional posters examining RG-101 pharmacokinetics, preclinical results to be presented-

-Regulus Earns $2.5 Million Milestone Payment from AstraZeneca-

- Achieved Key 2014 'Clinical Map Initiative' Goals to Advance microRNA Therapeutics Pipeline -

-Extended Follow-Up Shows 4/14 Patients Treated with a Single SC Dose of 2 mg/kg of RG-101 are Target Not Detected at Day 85 -

Accelerates RG-101 for HCV with Dual-Track Clinical Development Strategy; Top-Line, Single Dose, 4 mg/kg Results as Well as 2mg/kg Extended Follow Up Results from Ongoing Study to be Reported in Early February 2015

- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome -

- Demonstrated Human Proof-of-Concept; 'Clinical Map Initiative' Updated -